Results 201 to 210 of about 725,921 (266)

Gastrointestinal motility in microgravity: a critical review of multi-level mechanisms and model-dependent effects. [PDF]

Front Physiol
Niu Q, Mu T, Zhang J, Chen Y, Guo Z, Zhu Y, Li L.   +6 more
europepmc   +1 more source

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.

JAMA Intern Med
Ahmad AI, Garg S, Jacobs J, Ansari Z, Al-Din TJ, Almomani A, Valencia S, Vargo J, Chatterjee A, Siddiki H, Hong L, Nicolas MA, Miller A, Shah T.   +13 more
europepmc   +1 more source

Transglutaminase-mediated glycosylation improves the physicochemical properties and in vitro hypolipidemic activity of oyster peptides. [PDF]

Food Chem X
Huang Q, Chen Z, Tan M, Zheng H, Lin H, Gao J, Qin X, Cao W.   +7 more
europepmc   +1 more source

Alkaloids Mediate Multi-Level Modulation of Gastric Carcinogenesis: From Antibacterial and Anti-Inflammatory Actions to Antitumor Effects. [PDF]

Int J Mol Sci
Liu Y, Sun Z, Ouyang W, Liu K, Ma C, Lu F, Wang Q, Wang X, Cheng F.   +8 more
europepmc   +1 more source

Fasting gut hormone levels following long-term recovery from Anorexia Nervosa: A cross-sectional study. [PDF]

J Eat Disord
Kolb T, Tam FI, Förster Ribet C, Ohme M, Schlolaut LC, King JA, Roessner V, Dickson SL, Pariante CM, Borsini A, Perakakis N, Ehrlich S.   +11 more
europepmc   +1 more source

Distinctive patterns of glucagon and incretin responses to oral and isoglycaemic intravenous glucose load in fibrocalculous pancreatic diabetes. [PDF]

Sci Rep
Verma S, Dasgupta R, Anoop S, Jebasingh FK, Chowdury SD, Jose A, Varghese G, Christudoss P, Venkatesan P, Rebekah G, Horowitz M, Thomas N.   +11 more
europepmc   +1 more source

The Insulinotropic Action of Gastric Inhibitory Polypeptide

Canadian Journal of Physiology and Pharmacology, 1975
The effect of highly purified gastric inhibitory polypeptide (GIP) on immunoreactive insulin (IRI) secretion in the conscious fasted dog was investigated. Significant increases in IRI release were observed with intravenous administration of three different doses of GIP. These were accompanied by depression in fasting serum-glucose levels.
R A, Pederson, H E, Schubert, J C, Brown
openaire   +3 more sources

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

American Journal of Physiology-Endocrinology and Metabolism, 2004
The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstrated to inhibit gastric acid secretion and was proposed to possess “enterogastrone” activity. GIP effects on gastric emptying have not yet been studied. Fifteen healthy male volunteers (23.9 ± 3.3 yr, body mass index 23.7 ± 2.3 kg/m2) were studied with the intravenous
Meier, Juris J, Goetze, Oliver, Anstipp, Jens, Hagemann, Dirk, Holst, Jens Juul, Schmidt, Wolfgang E, Gallwitz, Baptist, Nauck, Michael A   +7 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

Best Practice & Research Clinical Endocrinology & Metabolism, 2004
The 42 amino acid polypeptide glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) is released from intestinal K-cells in response to nutrient ingestion. Based on animal studies, the peptide was initially assumed to act as an endogenous inhibitor of gastric acid secretion.
Michael A. Nauck, Juris Meier
exaly   +2 more sources